BioCentury
ARTICLE | Clinical News

CB-839: Phase I data

November 23, 2015 8:00 AM UTC

Data from 14 patients with MM or NHL in the open-label, dose-escalation, U.S. Phase I CX-839-002 trial showed that twice-daily 600 mg and thrice-daily 100-400 mg doses of CB-839 were well tolerated. T...